The stock price of
Cytori Therapeutics, Inc.
) gained 2.69% on Thursday, Jun 18, 2013, on the announcement of
an agreement with Medistem, Inc. As per the terms of the
agreement, Cytori gets the exclusive rights to use Medistem's
patent related to stem cell mediated treg activation (US Patent
BAXTER INTL (BAX): Free Stock Analysis Report
CYTORI THERAPEU (CYTX): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.
The licensed patent from Medistem strengthens the protection of
Cytori's autoimmune disease candidates developed on an
adipose-derived regenerative cell based platform.
We see this move as a positive for the company and in-line with
the company's strategy. Earlier, in a filing with the US
Securities and Exchange Commission (SEC), the company had
disclosed that it is looking for additional patents related to
its adipose-derived stem and regenerative cells platform.
We believe that strong patent protection is critical for Cytori
as several companies including
Baxter International Inc.
) are developing cell-based therapies.
Earlier this month, at the JMP Securities Healthcare Conference
2013, Cytori provided an encouraging update on its business.
Cytori, which generated revenues of $8.7 million in 2012, expects
revenues to jump to $15 million in 2013. Revenues are expected to
increase on the back of contract milestone payments from
government agencies like the US Department of Health and Human
Service's Biomedical Advanced Research and Development Authority
Cytori carries a Zacks Rank #2 (Buy). Other stocks, which appear
to be favorably placed, include
Jazz Pharmaceuticals Public Limited Company
) carrying a Zacks Rank #1 (Strong Buy).